Early menarche and childbirth accelerate aging-related outcomes and age-related 1

#### diseases: Evidence for antagonistic pleiotropy in humans 2

Yifan Xiang<sup>1</sup>, Vineeta Tanwar<sup>1</sup>, Parminder Singh<sup>1</sup>, Lizellen La Follette<sup>1</sup>, Pankaj Kapahi<sup>1\*</sup> 3

#### **Affiliations:** 4

- <sup>1</sup>The Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA 94945 5
- \*Corresponding author: Pankaj Kapahi, Email: pkapahi@buckinstitute.org. 6
- 7

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract: Aging can be understood as a consequence of the declining force of natural selection with age. 8 Consistent with this the antagonistic pleiotropic theory of aging suggests that aging results from the trade-offs 9 that promote early growth and reproduction. However, evidence for antagonistic pleiotropy in humans is 10 largely lacking. Using Mendelian Randomization (MR), we demonstrated that later ages of menarche or first 11 childbirth were genetically associated with longer parental lifespan, decreased frailty index, slower epigenetic 12 13 aging, later menopause, and reduced facial aging. Moreover, later menarche or first childbirth were also genetically associated with a lower risk of several age-related diseases, including late-onset Alzheimer's 14 disease (LOAD), type 2 diabetes, heart disease, essential hypertension, and chronic obstructive pulmonary 15 disease (COPD). We validated the associations between the age of menarche, childbirth, and the number of 16 childbirths with several age-related outcomes in the UK Biobank by conducting regression analysis of nearly 17 200,000 subjects. Our results demonstrated that menarche before the age 11 and childbirth before 21 18 significantly accelerated the risk of several diseases, and almost doubled the risk for diabetes, heart failure, 19 and quadrupled the risk of obesity, supporting the antagonistic pleiotropy theory. We identified 128 significant 20 single nucleotide polymorphisms (SNPs) that influenced age-related outcomes, some of which were involved 21 in known longevity pathways, including IGF1, growth hormone, AMPK, and mTOR signaling. Our study also 22 identified higher BMI as a mediating factor in causing the increased risk of certain diseases, such as type 2 23 diabetes and heart failure, in women with early menarche or early pregnancy, emphasizing the importance of 24 the thrifty gene hypothesis in explaining in part the mechanisms behind antagonistic pleiotropy. Our study 25 highlights the complex relationship between genetic legacies and modern diseases, emphasizing the need for 26 gender-sensitive healthcare strategies that consider the unique connections between female reproductive 27 health and aging. 28

#### Introduction 30

Given the decline in the force of natural selection with age, genes that influence aging and age-related diseases 31 are likely to be selected for their influence on early life events <sup>1</sup>. The theory of antagonistic pleiotropy posits 32 that inherent trade-off in natural selection, where genes beneficial for early survival and reproduction may 33 have costly consequences later, contributes to the aging process and age-related diseases <sup>1-3</sup>. Though evidence 34 for antagonistic pleiotropy has been observed in invertebrate models, evidence for causal relationships in 35 mammals, especially humans, is largely lacking <sup>4</sup>. The timing of reproductive events, such as menarche and 36 childbirth, has long been recognized as a crucial aspect of human life history and evolution. However, 37 accumulating evidence suggests that these reproductive milestones may have far-reaching implications <sup>5,6</sup>. 38

Considering reproductive events are largely regulated by genetic factors that can manifest the physiological 39 outcome later in life, we hypothesized that earlier or later onset of menarche and first childbirth could reflect 40 broader genetic influences on longevity and disease susceptibility, serving as proxies for biological aging 41 processes (fig. S1 and fig. S2). Two-sample and two-step Mendelian randomization (MR) analyses were 42 adopted to explore the genetic causal associations using the inverse variance weighted (IVW) model. After 43 preprocessing, there were 209 and 33 single nucleotide polymorphisms (SNPs) included in MR analyses for 44 the two exposures, age at menarche <sup>7</sup> and age at first birth <sup>8</sup>, respectively. 45

46

#### Later menarche was genetically associated with later aging outcomes 47

Since parental ages at death may reflect the genetic heritability of lifespan, parental ages at death were used 48 as general aging outcomes <sup>9</sup>. Compared to early menarche, later age at menarche was significantly 49 associated with later parental ages at death for mothers or fathers (OR=1.023, P= $1.84 \times 10^{-4}$ ; OR=1.020, 50  $P=7.88 \times 10^{-4}$  for father and mother's ages at death respectively) (Fig. 1A and Table S1-S3). Aging is the 51 biggest risk factor for frailty and several age-related diseases. Later age at menarche was associated with a 52 lower frailty index, which was calculated using a set of 49 self-reported questionnaire items on traits 53 covering health, presence of diseases and disabilities, and mental well-being  $^{10}$  (OR=0.977, P=5.75×10<sup>-3</sup>). 54 After excluding the instrumental variables (IVs) associated with body mass index (BMI), the significant 55 association between later menarche and outcomes remained based on the weighted median model (WMM) 56 for frailty index (OR=0.972, P=0.0202) and based on IVW for parental ages at death (OR=1.015, 57  $P=2.46\times10^{-2}$ ; OR=1.012, P=3.87\times10^{-2}). Next, we examined the associations between the age of menarche 58 and organ aging or age-related diseases (Fig. 1B). Later age of menarche was associated with later 59 menopause onset (OR=1.121, P= $2.11 \times 10^{-2}$  with WMM), lower risks of late-onset Alzheimer's disease 60 (LOAD) (OR=0.897, P= $3.88 \times 10^{-2}$ ), chronic heart failure (CHF) (OR=0.953, P= $2.80 \times 10^{-2}$ ), essential 61 hypertension (OR=0.990, P=1.99×10<sup>-8</sup>), facial aging (OR=0.983, P=2.16×10<sup>-9</sup>), and early onset chronic 62 obstructive pulmonary disease (COPD) (OR=0.838, P= $9.50 \times 10^{-4}$ ) and mildly higher risk of osteoporosis 63  $(OR=1.001, P=2.07 \times 10^{-2})$ . These associations were still significant after excluding SNPs associated with 64 BMI, except for CHF. One potential mechanism of antagonistic pleiotropy is accelerated cell growth and 65

division; therefore, we examined the relationship between menarche and certain cancers. Later age at

67 menarche was associated with lower risks of breast cancer (OR=0.859, P= $1.53 \times 10^{-2}$ ) and endometrial cancer

68 (OR=0.896, P= $9.02 \times 10^{-4}$ ) compared with early menarche (Fig. 1B).

## 69 Later age at first birth was genetically associated with later aging outcomes

- Next, we examined the associations between the age of childbirth and age-related outcomes. Compared to
- early first birth, later age at first birth was associated with lower frailty index (OR=0.937, P= $5.93 \times 10^{-11}$ ) and
- GrimAge, a measure of epigenetic aging (OR=0.447, P= $4.37 \times 10^{-2}$ ), and older parental ages at death
- 73 (OR=1.035, P= $6.88 \times 10^{-5}$  for father's age at death; OR=1.034, P= $1.78 \times 10^{-4}$  for mother's age at death) (Fig.
- 1A). Similar to results with the age of menarche, later age at first birth was associated with later menopause
- onset (OR=1.306, P= $3.08 \times 10^{-4}$ ), lower risks of type 2 diabetes (OR=0.890, P= $3.65 \times 10^{-6}$ ), CHF (OR=0.926,
- P= $2.56 \times 10^{-2}$ ), essential hypertension (OR=0.989, P= $1.54 \times 10^{-4}$ ), and gastrointestinal or abdominal disease
- (GAD) (OR=0.991, P= $1.29 \times 10^{-3}$ ). Most significant associations remained after the BMI-related SNPs were
- excluded, except for CHF (Fig. 1C and Table S3). Furthermore, later age at first birth was also significantly
- associated with a lower risk of cervical cancer (OR=0.999, P= $1.52 \times 10^{-2}$ ) but not breast and endometrial
- 80 cancers (Fig. 1C).

66

#### 81 BMI is an important mediator in significant associations

As BMI is an important modulator of aging <sup>11</sup>, we examined its role in explaining these associations. Based 82 on the two-sample MR analyses, significant associations between early menarche and CHF, and between 83 early first birth and CHF and cervical cancer, were not observed after excluding SNPs related to BMI (Fig. 84 1). To estimate the effect of BMI as the mediator, we further conducted two-step MR. Exposures of age of 85 menarche and age at first birth, and outcomes of frailty index, type 2 diabetes, and CHF, were included in 86 the two-step MR analysis. Later ages of menarche and first birth were associated with lower BMI 87  $(OR=0.948, P=2.73\times10^{-13}; OR=0.956, P=6.85\times10^{-5})$ . Higher BMI was associated with higher risks of type 2 88 diabetes (OR=2.391, P=4.65×10<sup>-156</sup>), CHF (OR=1.690, P=1.67×10<sup>-44</sup>), and cervical cancer (OR=1.001, 89  $P=3.16\times10^{-2}$ ). Significant pleiotropy was detected in the association between BMI and frailty index. Two-90 step MR showed that BMI significantly mediated the associations between menarche and, type 2 diabetes or 91 CHF (Table S4). BMI also significantly mediated the associations between first birth and, type 2 diabetes, 92 CHF, or cervical cancer (Table S4). As both early menarche and first birth were associated with higher BMI, 93 the BMI had a significant effect to explain the associations partially. Results of colocalization analysis 94 showed 5 SNPs associated with both the exposures and outcomes (Table S5). 95

## 96 Mechanisms explaining antagonistic pleiotropy

97 We identified 128 significant SNPs in the genes from the MR analysis for their association between age of 98 menarche or first birth with 15 aging and age-related disease outcomes. These SNPs were then listed according 99 to (i) the number of study outcomes they were associated with and (ii) their frequency of occurrence in the 100 European and global population. We chose to depict only the SNPs that were associated with greater than three

outcomes as shown in Fig. 2. The SNP rs2003476 in the CRTC1 gene was found to be associated with seven 101 aging and age-related disease outcomes (frailty index, LOAD, CHF, father's age at death, mother's age at death, 102 breast, and endometrial cancer). Previous studies have indicated that CRTC1 transcription domain is linked 103 with extending the lifespan in C. elegans <sup>12</sup> and a decrease in CRTC1 levels was found to be associated with 104 human AD<sup>13</sup>. Two other genes involved in the glutathione metabolism pathway, CHAC1 and GGT7, were also 105 found to be associated with four different aging outcomes (CHAC1 was associated with frailty index, diabetes, 106 COPD, and BMI; GGT7 was associated with father's age at death, hypertension, breast cancer and BMI) (Fig. 107 2). Importantly, the SNP in CHAC1 is a missense variant, suggesting its impact on protein translation and 108 potential contribution to disease biology. CHAC1 has recently been implicated in age-related macular 109 degeneration <sup>14</sup> and muscle wasting <sup>15</sup>. Posttranslational protein-lipid modification processes are known to 110 contribute to aging and age-related diseases <sup>16</sup>. N-myristoylation is one such process that is catalyzed by NMT 111 (N-myristoyltransferase)<sup>17</sup>, another intriguing gene candidate identified in our analysis. We found an 112 association of NMT1 with three aging outcomes: T2D, CHF, and endometrial cancer. Various myristoylated 113 proteins have been implicated in diverse intracellular signaling pathways<sup>18</sup> including AMP-activated protein 114 kinase (AMPK)<sup>19,20</sup>. It has been shown that NMT1 exerts synovial tissue-protective functions by promoting 115 the recruitment of AMPK to lysosomes and inhibiting mTORC1 signaling <sup>19</sup>. In addition, drugs targeting 116 NMTs (NMT1 and NMT2) have been suggested to be potent senolytics <sup>21</sup> and a target for treating or preventing 117 various diseases such as cancer <sup>22,23</sup> and heart failure <sup>24</sup>. Furthermore, modulating the evolutionarily conserved 118 N-myristoyl transferase NMT1 was shown to extend lifespan in yeast <sup>25</sup>. The full table of SNPs and their 119 population frequency and association with aging outcomes is provided in Table S6. 120

Canonical signaling pathways analysis. A total of 498 canonical signaling pathways related to 128 SNPs/gene 121 outcomes were identified based on the Ingenuity Pathway Knowledge Base (IPKB). After ranking the 122 identified canonical signaling pathways according to their adjusted P-values, the top 25 canonical signaling 123 pathways with a p-value  $< 10^{-2}$  enriched by SNPs/genes involved in the age of menarche and first birth are 124 represented in Fig. 3A. The top enriched canonical signaling pathways fell into these broader categories: (1) 125 Developmental and cellular signaling pathways such as BMP, IGF-1, and growth hormone signaling; (2) 126 Neuronal signaling and neurological disorders that include amyloid processing, activation of NMDA receptors 127 and postsynaptic events, and glioma signaling; (3) Metabolic signaling pathways such as insulin receptor, 128 mTOR, and leptin signaling; (4) Immunological and inflammatory signaling pathways, which include 129 lymphotoxin β receptor and TREM1 signaling; (5) Cardiovascular and muscular signaling pathways including 130 the role of NFAT in cardiac hypertrophy. In addition to canonical pathways, SNPs/genes were shown to be 131 further associated with diseases and functions. IPA showed a total of 80 diseases and functions associated with 132 age at menarche and first birth. These associated diseases and functions were rated according to their adjusted 133 P-values, and the top 20 enriched categories with a P-value  $< 10^{-5}$  were selected and depicted in Fig. 3B. 134

Gene network analysis and drug interactions. Besides pathway and disease associations, the 128 SNPs/genes
 were further connected to identify 11 functional networks using IPA. These IPA networks were ranked based

on their consistency scores. The top 5 networks included a range of 13-17 genes with scores above 25, 137 indicating robust regulatory analysis <sup>26</sup> (**Table S7**). The top networks were mainly connected to the following 138 functions: Cellular interaction/signaling/development (Fig. 3C), cell death and survival, cancer, 139 gastrointestinal, reproductive (Fig. 3C), neurological (Fig. 3D), and cardiovascular system, development, 140 function, diseases. These results support the notion that dynamic cellular interactions and the development of 141 various vital organ systems influenced by age at menarche and first birth also influence age-related diseases. 142 The two top IPA networks were further outlined in Fig. 3C and 3D. To further explore the drugs targeting 143 genes associated with age at menarche and first birth, we conducted an analysis using ChEMBL<sup>27</sup> and 144 DrugBank databases<sup>28</sup>. This examination revealed that a total of 11 FDA-approved drugs target the identified 145 genes (PRKAG2, SCN2A, DPYD, MC3R, AKT, MAPK, KCNK9, TACR3, HTR4, KCNB2, RXRG) (Table S8). 146

# Population validation for associations between age at menarche, or first live birth, or number of births with age-related outcomes

Next, we validated the genetic associations in the population cohort of the UK Biobank. 264,335, 184,481, 149 and 259,758 participants were included for independent variables of age at menarche, age at first live birth. 150 and number of births, respectively (Table S9). Ages at menarche were divided into 5 age groups, <11y, 11-151 12y, 13-14y, 15-16y, and >16y. The probability of living to 80 years old, having menopause  $\geq$  50 years old, 152 risk of diabetes, high blood pressure (HBP), heart failure, COPD, breast cancer, endometrial cancer, and 153 obesity were compared among the 5 age groups of menarche. Each of the outcomes was compared between 154 the highest and lowest education levels and 3 BMI categories (18.5-24.9, 25-29.9, and  $\geq$  30) among the 5 155 age groups (Fig. 4A-I). The ORs for each age group were calculated based on the coefficients ( $\beta$ ) in logistic 156 regression after including confounders of smoking, alcohol, education, and BMI. Compared to the group 157 with menarche under 11 years old, which generally had the highest risk, females with menarche at 13-14y 158 had the highest probability of living to 80 years old (OR=1.412, P<0.001) and having menopause  $\geq$  50 years 159 old (OR=1.146, P<0.001), and had the lowest risk of diabetes (OR=0.773, P<0.001), heart failure 160 (OR=0.835, P<0.001), and COPD (OR=0.728, P<0.001). The group with menarche at 15-16y had the lowest 161 risks of high blood pressure (HBP) (OR=0.793, P<0.001) and obesity (OR=0.337, P<0.001). Females with 162 menarche >16y had the lowest risks of breast cancer (OR=0.832, P<0.05) and endometrial cancer 163 (OR=0.641, P<0.05) compared to females with menarche <11y (Table S10). 164

Ages at first birth were divided into 5 age groups, <21y, 21-25y, 26-30y, 31-35y, and >35y. The probability of living to 80 years old, having menopause  $\geq$  50 years old, risk of diabetes, AD, HBP, heart failure, cerebral infarction, digestive system disease, cervical cancer, and obesity were compared among the 5 age groups of first live birth. Compared to the group with first live birth under 21 years old, which generally had the highest risks, females with first live birth at 21-25y had the highest probability to live to 80 years old (OR=1.667, P<0.001), and females with first live birth at 26-30y had the highest probability to have

171 menopause  $\geq$  50 years old (OR=1.184, P<0.001) and lowest risk of cervical cancer (OR=0.587, P<0.01).

- Females with first live birth at 31-35y had the lowest risk of diabetes (OR=0.612, P<0.001). Females with
- 173 first live birth >35y had the lowest risk of having AD (OR=0.474, P<0.01), HBP (OR=0.587, P<0.001),
- heart failure (OR=0.446, P<0.001), cerebral infarction (OR=0.485, P<0.001), digestive system disease
- 175 (OR=0.569, P<0.001), and obesity (OR=0.416, P<0.001) (Fig. 4J-S).
- Females with the number of births from 0 to 4 were included. Compared to no birth, females with 3 births
- had the highest probability of living to 80 years old (OR=1.818, P<0.001) and having menopause  $\geq$  50 years
- old (OR=1.562, P<0.001). Females with 4 births had the highest risk of diabetes (OR=1.399, P<0.001), AD
- 179 (OR=1.676, P<0.001), HBP (OR=1.274, P<0.001), heart failure (OR=1.439, P<0.001), cerebral infarction
- 180 (OR=1.470, P<0.001), digestive system disease (OR=1.370, P<0.001), and obesity (OR=1.327, P<0.001) but
- lowest risk of breast cancer (OR=0.869, P<0.001) (Fig. 4T-AC). The significant estimated effect ( $\beta$ ) of each
- group compared to the youngest age groups of menarche and first live birth and 0 birth group and the ability to explain the variability of outcomes in regression analysis are exhibited in **Table S10**.
- 184 To estimate the combined effect of age at menarche and first live birth on diabetes, HBP, heart failure, and
- 185  $BMI \ge 30$ , participants were divided into 25 groups according to the menarche and first live birth ages.
- 186 Females with menarche<11y and first live birth<21y had higher risks of diabetes (OR=1.881, P<0.001),
- 187 HBP (OR= 1.436, P<0.05), heart failure (OR= 1.776, P<0.01), and BMI $\ge$  30 (OR= 4.417, P<0.001)
- 188 compared to females with menarche of 13-14y and first live birth of 26-30y (Table S11 and fig. S3).
- 189

The timing of reproductive milestones such as the age of menarche and age at first birth is partly governed by 190 genetic factors, which may exert lasting impacts on an individual's health trajectory. Our study finds support 191 for antagonistic pleiotropy by demonstrating that genetic variants that drive early menarche or early pregnancy 192 accelerate several aging outcomes, including parental age, frailty index, and several age-related diseases such 193 as diabetes and dementia. These results were validated in a cohort from the UK biobank, showing that women 194 with early menarche, or early pregnancy, were associated with accelerated aging outcomes and increased risk 195 of several age-related diseases. These results are also consistent with the disposable soma theory that suggests 196 aging as an outcome tradeoff between an organism's investment in reproduction and somatic maintenance and 197 repair. Consistent with a recent study suggesting the relation of early first birth with a higher likelihood of 198 frailty<sup>29</sup>, our MR analysis provided a strong association between early age of first birth and GrimAge, a DNA 199 methylation based marker to predict epigenetic age. Our findings align with the observed negative genetic 200 correlation between reproductive traits and lifespan that individuals with higher polygenetic scores for 201 reproduction have lower survivorships to age 76<sup>30</sup>. Prior studies linking the female reproductive factors with 202 aging are either limited to results obtained from observational studies <sup>31,32</sup> or are limited to few outcomes such 203 as brain disorders <sup>33,34</sup>. Furthermore, the origins of aging in humans have also been considered adaptive <sup>35</sup>. 204

Using MR, we identified 128 SNPs associated with early menarche or first birth that significantly influence age-related outcomes. Among the top 25 enriched canonical signaling pathways, those involved in developmental and cellular processes are particularly significant in determining the timing of menarche and

first childbirth, with nearly half of these pathways (12 out of 25) falling into this category. These 208 developmental and cellular signaling pathways work together to regulate continuous growth and involution 209 from puberty through menopause <sup>36</sup>. Interestingly, known longevity pathways such as insulin-like growth 210 factor 1 (IGF1), growth hormone (GH) signaling, melatonin signaling, and bone morphogenetic protein (BMP) 211 signaling, seem to play a crucial role in regulating the timing of these reproductive events. IGF-1 signaling 212 promotes the growth and development of reproductive organs and tissues <sup>37-39</sup>, but is also a conserved 213 modulator of longevity <sup>40-43</sup>. Melatonin, known for regulating circadian rhythms, influences the timing of 214 menarche through its effects on the hypothalamic-pituitary-gonadal axis <sup>44</sup> and is postulated to modulate 215 oxidative, inflammatory, and autophagy states <sup>45</sup>. Furthermore, different processes in early life such as cell 216 proliferation or differentiation <sup>46</sup>, ovarian function, and follicular development <sup>47-49</sup> are dependent on BMP 217 signaling. However, increased BMP signaling also contributes significantly to AD pathology <sup>50</sup> and 218 impairments in neurogenesis and cognitive decline associated with aging <sup>51</sup>. Aberrant BMP signaling is also 219 shown to be associated with age-related metabolic and cardiovascular diseases <sup>52,53</sup>. Additionally, growth 220 hormone signaling is not only vital for development during childhood and puberty <sup>54</sup> but also impacts longevity 221 <sup>55</sup>. Besides signaling pathways, genes in age at menarche and first childbirth were connected in gene-gene 222 interaction networks. In IPA network 1, most genes were connected with either AKT or genes encoding for 223 follicle-stimulating hormone (FSH), luteinizing hormone (LH), leptin receptor (LEPR), and inhibin subunit 224 beta A (INHBA). AKT signaling is implicated in oocyte maturation and embryonic development <sup>56</sup> and 225 mediates pregnancy-induced cardiac adaptive responses <sup>57</sup>. AKT signaling also mediates age-related disease 226 pathologies, such as AD <sup>58</sup>. Major ovarian functions are controlled by FSH (follicular growth, cellular 227 proliferation, and estrogen production) and LH (oocyte maturation, ovulation, and terminal differentiation of 228 follicles) which in turn are modulated by other ovarian factors such as INHBA (a subunit of activin and inhibin) 229 <sup>59,60</sup>. Endocrine alterations at advanced aging or reproductive aging <sup>61</sup> are marked by changes in FSH and LH 230 due to altered feedback resulting from the ovarian decline in sex steroids, inhibin A, and inhibin B production 231 <sup>62-64</sup>. In IPA network 2, the hub genes are connected mostly with extracellular signal-regulated kinases (ERK), 232 Similar to AKT, ERK is also a member of the mitogen-activated kinase family (MAPK), a highly conserved 233 signaling pathway that plays a vital role in transducing extracellular signals into a wide range of cellular 234 responses <sup>65,66</sup>, maintaining tissue integrity during aging <sup>67</sup>, and mediating age-related disease pathology <sup>58,68</sup>. 235 These studies underscore the importance of considering that dysregulation or abnormal activation of any of 236 these pathways could contribute to the onset of late-life diseases consistent with antagonistic pleiotropy in 237 humans<sup>2,69</sup>. 238

The thrifty gene hypothesis provides a compelling framework to explain antagonistic pleiotropy, particularly in the context of modern health challenges. The thrifty gene hypothesis suggests that genes favoring efficient energy storage were advantageous in historical periods of food scarcity, helping individuals survive through famines. However, in today's environment of abundant food, the same genes contribute to obesity and metabolic diseases like diabetes. Similarly, in the context of antagonistic pleiotropy, we hypothesize that genes that enhance early-life reproductive success favor efficient energy storage to support reproductive

health. This is supported by our observation that early pregnancy is associated with increasing BMI, a 245 recognized key factor in systemic aging <sup>70,71</sup>. In support of this, we found a lack of significant association 246 between early menarche or age at first birth for CHF and cervical cancer after removal of BMI as a 247 confounder in MR analysis. Based on regression analysis at the population level (Fig. 4), higher BMI was 248 associated with higher risks of cardiovascular diseases and diabetes. Thus, an increase in BMI is one of the 249 factors that explains the increased risk of age-related disease seen due to the exposure of early pregnancy or 250 the prevalence of genes that enhance early reproductive success. These results are also consistent with 251 calorie restriction being a robust way to extend healthspan and lifespan in many species <sup>72</sup>. 252

Several limitations of our study need to be considered. Firstly, all the associations are explored at the genetic 253 level with MR and population level with the UK Biobank. However, to confirm causal relationships, further 254 validation through in vitro and in vivo research is essential. Secondly, though we excluded confounder-related 255 SNPs and addressed potential pleiotropic effects, there may also be potential bias which could be addressed 256 by extending these findings to other populations. Thirdly, significant heterogeneity and pleiotropy remained 257 in some association analyses, which need further exploration. Given the increasing age of first childbirth in 258 modern times, the ideal period of first childbirth for both slowing down female aging and benefiting fetal 259 development needs more research <sup>73</sup>. In summary, our study underscores the complex relationship between 260 genetic legacies and modern diseases. Understanding these genetic predispositions can inform public health 261 strategies and their relevance to age-related disease outcomes in women of various ethnic groups. For example, 262 interventions could be tailored not only to mitigate the risks associated with early reproductive timing but also 263 to address lifestyle factors exacerbating conditions linked to thrifty genes, like diet and physical activity. 264

265

#### 266 Methods

All the MR research data is from the public genome-wide association studies (GWAS) databases of the IEU Open GWAS project (<u>https://gwas.mrcieu.ac.uk/</u>) and PubMed. The target analysis is based on public datasets. The population data is from the UK Biobank. No definite personal information was included. No additional ethical approval was required for our study.

#### 271 Exposure data

2 traits were included as female reproductive activity exposures, involving age at menarche <sup>7</sup> (GWAS ID:
ebi-a-GCST90029036) and age at first birth <sup>8</sup> (GWAS ID: ebi-a-GCST90000048).

## 274 Outcome data

- 275 The aging outcomes involved general aging, organ aging/disease, and organ cancers (Table S1). Frailty
- index <sup>74</sup> (GWAS ID: ebi-a-GCST90020053), father's age at death<sup>75</sup> (GWAS ID: ebi-a-GCST006700),
- 277 mother's age at death <sup>75</sup> (GWAS ID: ebi-a-GCST006699), and DNA methylation GrimAge acceleration <sup>76</sup>
- 278 (GWAS ID: ebi-a-GCST90014294) were included as general aging outcomes. Specific aging diseases and
- aging levels included age at menopause onset <sup>7</sup> (GWAS ID: ebi-a-GCST90029037), late-onset Alzheimer's

280 disease <sup>77</sup> (LOAD) (PMID: 30820047), osteoporosis <sup>78</sup> (GWAS ID: ebi-a-GCST90038656), and type 2

- diabetes <sup>79</sup> (GWAS ID: ebi-a-GCST90018926), chronic heart failure <sup>79</sup> (CHF) (GWAS ID: ebi-a-
- 282 GCST90018806), essential hypertension (GWAS ID: ukb-b-12493), facial aging (GWAS ID: ukb-b-2148),
- eye aging <sup>80</sup> (PMID: 36975205), cirrhosis (GWAS ID: finn-b-CIRRHOSIS\_BROAD), chronic kidney
- disease <sup>81</sup> (CKD) (GWAS ID: ebi-a-GCST008026), early onset chronic obstructive pulmonary disease
- 285 (COPD) (GWAS ID: finn-b-COPD\_EARLY), and gastrointestinal or abdominal disease (GAD) <sup>78</sup> (GWAS
- ID: ebi-a-GCST90038597). Organ cancers included breast cancer <sup>79</sup> (GWAS ID: ebi-a-GCST90018799),
- ovarian cancer <sup>79</sup> (GWAS ID: ebi-a-GCST90018888), endometrial cancer <sup>82</sup> (GWAS ID: ebi-a-
- 288 GCST006464), and cervical cancer (GWAS ID: ukb-b-8777).

#### 289 SNPs selection

- We identified single nucleotide polymorphisms (SNPs) associated with exposure datasets with  $p < 5 \times 10^{-8}$
- <sup>83,84</sup>. In this case, 249 SNPs and 67 SNPs were selected as eligible instrumental variables (IVs) for exposures
- of age at menarche and age at first birth, respectively. All selected SNPs for every exposure would be
- clumped to avoid the linkage disequilibrium ( $r^2 = 0.001$  and kb = 10,000). Then we identified whether there

were potential confounders of IVs associated with the outcomes based on a database of human genotype-

phenotype associations, PhenoScanner V2  $^{85,86}$  (http://www.phenoscanner.medschl.cam.ac.uk/), with a threshold of p < 1 × 10<sup>-5</sup>. IVs associated with education, smoking, alcohol, activity, and other confounders related to outcomes would be excluded. During the harmonization process, we aligned the alleles to the human genome reference sequence and removed incompatible SNPs. Subsequent analyses were based on the

- merged exposure-outcome dataset. We calculated the F statistics to quantify the strength of IVs for each
   exposure with a threshold of F>10<sup>87</sup>. If the effect allele frequency (EAF) was missing in the primary
   dataset, EAF would be collected from dsSNP (https://www.ncbi.nlm.nih.gov/snp/) based on the population
- dataset, EAF would be collected from dsSNP (<u>https://www.ncbi.nlm.nih.gov/snp/</u>) based on the population
   to calculate the F value.

#### 303 MR analysis

All analysis was performed using R software (version 4.3.1, R Foundation for Statistical Computing,

- Vienna, Austria) and RStudio software (version 2023.09.0 Posit, PBC, Boston, USA) with TwoSampleMR
  (version 0.5.7) and MRPRESSO (version 1.0) packages.
- Five two-sample MR methods were applied for analysis, including inverse variance weighted model (IVW), MR Egger regression model (MER), weighted median model (WMM), simple mode, and weighted mode. A pleiotropy test was used to check if the IVs influence the outcome through pathways other than the exposure of interest. A heterogeneity test was applied to ensure whether there is a variation in the causal effect estimates across different IVs. Significant heterogeneity test results indicate that some instruments are invalid or that the causal effect varies depending on the IVs used. MRPRESSO was applied to detect and correct potential outliers of IVs with NbDistribution = 10,000 and threshold p = 0.05. Outliers would be
- excluded for repeated analysis. The causal estimates were given as odds ratios (ORs) and 95% confidence

intervals (CI). Leave-one-out analysis was conducted to ensure the robustness of the results by sequentially
excluding each IV and confirming the direction and statistical significance of the remained SNPs.

In two-step MR, we mainly use IVW to access the causal associations between exposure and outcome,

exposure and mediator, and mediator and outcome. Body mass index (BMI) (GWAS ID: ukb-b-19953) was

applied as a mediator. Similar steps of two-sample MR were repeated in the analysis after excluding

320 confounders. The mediator effect (ME) and direct effect (DE) were calculated. The MEs were calculated

with the formula: beta1  $\times$  beta2; DEs were calculated according to the formula: beta – (beta1  $\times$  beta2), beta

322 stands for the total effect obtained from the primary analysis, beta1 stands for the effect of exposure on the

mediator, and beta2 stands for the effect of the mediator on the outcome.

#### 324 Colocalization analysis

To improve the robustness of our research, colocalization analysis was conducted with packages gwasglue

326 (version 0.0.0.9000), coloc (version 5.2.3), and gassocplot (version 1.0) between the exposures and

327 outcomes revealing significant associations after BMI-related SNPs were excluded. SNPs with significant P

values in single SNP OR analysis were set as target SNPs. SNP-level colocalization was conducted with

50kb <sup>88</sup> windows around each target SNP. EAF was set to 0.5 if it was missed in the primary datasets. The

Bayesian algorithm in the coloc package generates posterior probabilities (PP) for the hypothesis that both

traits are associated and share the same single causal variant at a specific locus  $(H_4)^{89}$ . SNP with significant

results in the colocalization analysis would be removed and two-sample MR analyses would be conducted again.

## 334 Target Analysis

We employed the Ingenuity Pathway Analysis (IPA) software (version 01-22-01; Ingenuity Systems; QIAGEN) 335 to investigate various gene-related aspects associated with age at first birth and menarche. IPA is a widely 336 used bioinformatics tool for interpreting high-throughput data <sup>90</sup>. Briefly, the SNPs/genes from MR analysis 337 were uploaded into Qiagen's IPA system for core analysis and then the outcome was overlaid with the global 338 molecular network in the Ingenuity pathway knowledge base (IPKB). IPA was performed to identify canonical 339 pathways, diseases, and functions, and to investigate gene networks. Additionally, the Chemical Biology 340 Database (ChEMBL) (https://www.ebi.ac.uk/chembl/). a large-scale database of bioactive molecules for drug 341 discovery <sup>27</sup>, and the DrugBank database <sup>28</sup>, a comprehensive database on FDA-approved drugs, drug targets, 342 mechanisms of action, and interactions (https://go.drugbank.com/), were used to identify candidate genes 343 targeted by approved drugs in clinical trials or under current development phases. 344

## 345 **Population validation**

The MR results were further validated based on the UK Biobank with package stats (version 4.3.1). In addition to age at menarche and first live birth, the number of births is listed as an independent variable for the validation analysis. Based on the significant associations, regression analysis was adopted to explore the effect of independent variables and related confounders on outcomes. Ages at menarche were divided into 5 age

groups, <11y, 11-12y, 13-14y, 15-16y, and >16y. Ages at first live birth were divided into 5 age groups, <21y, 350 21-25y, 26-30y, 31-35y, and >35y. Females with the number of births from 0 to 4 were included. Education 351 was divided into 7 levels based on the degrees. Smoking was divided into 2 categories, ever smoking or not. 352 Drinking was divided into 3 categories, never, previous, and current drinking. BMI was divided into four 353 categories, <18.5, 18.5-24.9, 25-29.9, and  $\geq$  30 based on the average value of 4 records. The outcome results 354 were preprocessed based on the baseline information collection, follow-up outcome, surgical history, and ICD-355 10 diagnosis summary. Logistic regression was used for the analysis of disease risks (categorical variables). 356 The coefficients  $(\beta)$  in logistic regression were log-odds ratios. Although the continuous variables exhibited 357 mild to moderate skewed distributions, considering the large sample size, linear regression was used for the 358 analysis of age at death, menopause age, and BMI in the first step. Then logistic regression was applied to 359 confirm the robustness of the results with the outcome of death age  $\geq 80$ , menopause age  $\geq 50$ , and BMI  $\geq 30$ . 360 Confounders for regression analysis I include education, smoking, and drinking. Confounders for regression 361 analysis II include education, smoking, drinking, and BMI. Variance Inflation Factors (VIF) were calculated 362 for each predictor in regression analysis to avoid multicollinearity. Values of VIF were less than 1.5 for each 363 predictor. For outcomes of diabetes, HBP, heart failure, and BMI≥30, the combined effect of age at menarche 364 and first birth was analyzed. 179.821 participants were divided into 25 groups according to the menarche and 365 first live birth age groups. All other groups were compared to the group with menarche of "13-14y" and the 366 first birth of "26-30y" in logistic regression (confounders including education, smoking, drinking, and BMI 367 for diabetes, HBP, and heart failure; including education, smoking, and drinking for  $BMI \ge 30$ ). 368

- **Data and materials availability:** All data are available in the main text, supplementary materials, or public
  database. The population data is available through the UK Biobank.
- 372 Acknowledgments: We thank the Kapahi Lab at Buck Institute for helpful discussions. This research has
- been conducted using the UK Biobank Resource under Application Number 151101. Funding: Hevolution
- Foundation (PK). National Institute of Health grant R01AG068288 and R01AG045835 (PK). Larry L.
- Hillblom Foundation (PK), Larry L. Hillblom Foundation (PS). Author contributions: Conceptualization:
- 376 YX, VT, PS, LLF, and PK. MR analysis and UK biobank validation: YX. Gene target analysis: VT. Funding
- acquisition: PK and PS. Writing original draft: YX, PS, and VT. All authors reviewed and edited the
- 378 manuscript.
- 379 **Competing interests:** Authors declare that they have no competing interests.
- 380 Supplementary Materials
- 381 Figs. S1 to S3
- Tables S1 to S11
- 383

medRxiv preprint doi: https://doi.org/10.1101/2024.09.23.24314197; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .





Organ aging/Disease	Age at menopause onset	Υ	1.355 (1.180 – 1.555)		<b>⊢</b> −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−	1.59e-05
		Ν	1.386 (1.184 - 1.624)		· · · · · · · · · · · · · · · · · · ·	1.15e-05
	Type 2 diabetes	Υ	0.890 (0.847 - 0.935)			3.65e-06
		Ν	0.901 (0.853 - 0.951)	<b>⊢−−−</b> 1		1.43e-04
	CHF	Υ	0.926 (0.866 - 0.991)	H		2.56e-02
		Ν				3.34e-01
	Essential hypertension	Y	0.989 (0.984 - 0.995)	H		1.54e-04
		Ν	0.992 (0.986 - 0.997)	H		2.52e-03
	GAD	Y	0.991 (0.985 - 0.996)	н		1.29e-03
		N	0.990 (0.984 - 0.996)	H		1.82e-03
Organ cancer	Cervical cancer	Υ	0.999 (0.998 - 1.000)			1.59e-02
		Ν	_			6.02e-02
				0.9 1	1.5	

Lower risk (Small) Higher risk (Large)

Figure 1. Genetic associations between exposures and outcomes. (A), genetic associations between 384 exposures and general aging. Later age at menarche was associated with a lower frailty index and higher 385 parental ages at death. Later age at first birth was associated with lower frailty index and GrimAge and 386 higher parental ages at death. (B), genetic associations between age at menarche and outcomes of organ 387 aging and diseases as well as organ cancer. Later age at menarche was associated with later age at 388 menopause onset and lower risks of LOAD, CHF, essential hypertension, facial aging, early onset COPD, 389 breast cancer, and endometrial cancer. (C), genetic associations between age at first birth and outcomes of 390 organ aging and diseases as well as organ cancer. Later age at first birth was associated with later age at 391 menopause onset and lower risks of type 2 diabetes, CHF, essential hypertension, gastrointestinal or 392 abdominal disease, and cervical cancer. The significant associations were not detected after BMI-related 393 SNPs excluded for outcomes of CHF and cervical cancer. BMI included, BMI-related SNPs included; CHF, 394 chronic heart failure; GAD, gastrointestinal or abdominal disease. 395

							Ş	ę.	use										
Exposure	Gene	SNP	Eur SNP Frequency	Global SNP Frequency	EI	Fathers	Mother	GrimA <sup>ge</sup>	LOA	0 <sup>SO</sup>	<i>qz</i> 1	CH En	EA EA	Copy		BMI			
Menarche	CRTC1	rs2003476#	C=0.40991	C=0.46903															
Menarche	TRPM3	rs1360201#	T=0.48208	T=0.45743															
Menarche	NIMIK	rs35375873 <sup>\$</sup>	C=0.12425	C=0.10196															
Menarche	DZANK1	rs6045400#	G=0.78072	G=0.74726															
Menarche	CHAC1	rs112036939*	T=0.02178	T=0.019887															
Menarche	USP35	rs2297605#	A=0.42044	A=0.40012															
Menarche	HTR4	rs9325098	T=0.24744	T=0.24372															
Menarche	INO80	Rs561821&	T=0.37147	T=0.37553															
Menarche	GGT7	rs7273470#	C=0.22064	C=0.21895															
Menarche	MAPK3	rs57149692@	C=0.40410	C=0.43346															
Menarche	SMARCAD1	rs183993#	A=0.56910	A=0.54284															
Menarche	C2orf74	rs17006627#	C=0.1929	C=0.19119															
Menarche	KCTD9	rs17053711#	A=0.26043	A=0.23871															
Menarche	Cllorf58	rs117947332#	C=0.04893	C=0.04341											-				
Menarche	DLGAP1	rs12607903#	T=0.722209	T=0.709937											-		Ef	fec	t
Menarche	TKT	rs141829833&	T=0.02352	T=0.01949											-			1	8.1
Menarche	AKT3	rs1973284#	G=0.67100	G=0.57113			+	-							+				
Menarche	KDM4B	rs2251561#	T=0.23459	T=0.23748			+	-					-		-				
Menarche	USP49	rs2254479#	A=0.540383	A=0.547857			-											- 0	,
Menarche	EEFSEC	rs3849531#	T=0.28151	T=0.35538			+								-				
Menarche	KCNK9	rs62520182#	T=0.15894	T=0.12578				-	-						-				
Menarche	TACR3	rs75544266#	T=0.04718	T=0.04087									-		-				
Menarche	TRIM41	rs7727787#	A=0.128488	A=0.121687			+								-			-	2.8
Menarche	NR5A1	rs2297605#	A=0.42044	A=0.40012	-		+								-				
Menarche	JADE2	rs13179411#	T=0.10225	T=0.08157			+								-				
Menarche	BRWD1	rs4818008#	A=0.38583	A=0.36226	1		+						+		+				
Menarche	BANF2	rs852033&	C=0.7050	C=0.6298			+	-					-		-				
Menarche	TTC26	rs113013060#	A=0.02158	A=0.01676	-		+	-				-	-						
Menarche	SULF2	rs6066454#	T=0.35251	T=0.31344			+	-				-							
Menarche	NMT1	rs9913787#	A=0.28846	A=0.26612	-		+												
Menarche	HSPE1P19	rs9681954&	C=0.60064	C=0.54979			+						-						
Menarche	BMPR2	rs190286519#	T=0.06894	T=0.05851			+				+		$\vdash$						
AFB	TRAF3	rs72704712#	G=0.16533	G=0.14575									-						
AFB	NOL4L	rs293566#	C=0.333621	C=0.370718											+	$\square$			
AFB	SORCS3	rs12250380#	G=0.51992	G=0.51992		$\vdash$	+				-				+				
AFB	TEX14	rs7359501#	T=0.3046	T=0.26923			+						+		-				

397 Figure 2. List and heatmap of SNPs/genes from post-MR analysis showing an association between age 398 at menarche and first birth with three or more aging outcomes. Genomic region location for each variant 399 is depicted by different characters: intron variant<sup>#</sup>; 2KB upstream variant; Missense variant<sup>\*</sup>; Intergenic 400 variant<sup>&</sup>; Regulatory region variant<sup>@</sup>. Heatmap is representative of an association of each gene/SNP with 401 different aging outcomes. Red bar represents a harmful association (-beta for Father's DA, Mother's DA, and 402 menopause; +beta for other outcomes); Blue bar represents a beneficial association (+beta for Father's DA, 403 Mother's DA, and menopause; -beta for other outcomes ); White bar represents no association. AFB; age at 404 first birth; FI, frailty index; Father's DA, father's age at death; Mother's DA, mother's age at death; 405 Menopause, age at menopause; LOAD, late-onset Alzheimer's disease; OS, osteoporosis; T2D, type II 406 diabetes; CHF, chronic heart failure; EH, essential hypertension; FA, facial aging; COPD, chronic obstructive 407 pulmonary disease; GAD, gastrointestinal or abdominal disease; BC, breast cancer; EC, endometrial cancer; 408 BMI, body mass index. 409

410

## medRxiv preprint doi: https://doi.org/10.1101/2024.09.23.24314197; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpendicular.

#### perpetuity. It is made available under a CC-BY 4.0 International license .

Α			
Canonical Signaling Pathways	-log <sub>10</sub> ( <i>p</i> -value) Fraction of genes that are involved in the pathway		Genes belonging to the pathway
Transcriptional Regulatory Network in Embryonic Stem Cells	2.31	0.0427	AKT3,BMPR2,IGF1R,INHBA,MAPK1,MAPK3,SMARCAD1
Leptin Signaling in Obesity	2.31	0.0658	AKT3,LEPR,MAPK1,MAPK3,PRKAG2
Activation of NMDA receptors and postsynaptic events	2.31	0.0595	CAMK4,DLG2,MAPK1,MAPK3,PRKAG2
Cachexia Signaling Pathway	2.31	0.0245	AKT3,BMPR2,DDIT4,IGF1R,INHBA,MAPK1,MAPK3,PRKAG2,PTH2R
BMP signaling pathway	2.31	0.0549	BMPR2,CAMK4,MAPK1,MAPK3,PRKAG2
Signaling by Activin	2.31	0.176	INHBA,MAPK1,MAPK3
PFKFB4 Signaling Pathway	2.29	0.0816	MAPK1,MAPK3,PRKAG2,TKT
Amyloid Processing	2.28	0.0784	AKT3,MAPK1,MAPK3,PRKAG2
Intrinsic Pathway for Apoptosis	2.28	0.0727	AKT3,MAPK1,MAPK3,NMT1
Lymphotoxin β Receptor Signaling	2.28	0.0727	AKT3,MAPK1,MAPK3,TRAF3
IGF-1 Signaling	2.28	0.0476	AKT3,IGF1R,MAPK1,MAPK3,PRKAG2
Docosahexaenoic Acid (DHA) Signaling	2.23	0.028	AKT3,MAPK1,MAPK3,PRKAG2,RXRG,STXBP4,SYT14
IL-22 Signaling	2.18	0.125	AKT3,MAPK1,MAPK3
Glioma Signaling	2.03	0.04	AKT3,CAMK4,IGF1R,MAPK1,MAPK3
Growth Hormone Signaling	2.02	0.0563	IGF1R,MAPK1,MAPK3,RPS6KC1
CLEAR Signaling Pathway	2.02	0.0246	AKT3,BMPR2,DDIT4,IGF1R,MAPK1,MAPK3,PRKAG2
Melatonin Signaling	2.02	0.0556	MAPK1,MAPK3,PRKAG2,RORA
Extra-nuclear estrogen signaling	2.02	0.0548	AKT3,IGF1R,MAPK1,MAPK3
TREM1 Signaling	1.98	0.0519	AKT3,MAPK1,MAPK3,NLRC3
mTOR Signaling	1.98	0.028	AKT3,DDIT4,MAPK1,MAPK3,PRKAG2,RPS6KC1
Insulin Receptor Signaling	1.98	0.0357	AKT3,MAPK1,MAPK3,PRKAG2,STXBP4
Estrogen-Dependent Breast Cancer Signaling	1.94	0.0488	AKT3,IGF1R,MAPK1,MAPK3
Transcriptional Regulation by NPAS4	1.94	0.0857	BMAL1,MAPK1,MAPK3
Role of NFAT in Cardiac Hypertrophy	1.94	0.0268	AKT3,CAMK4,IGF1R,MAPK1,MAPK3,PRKAG2
RHO GTPases Activate WASPs and WAVEs	1.94	0.0833	CYFIP2,MAPK1,MAPK3
Dilated Cardiomyopathy Signaling Pathway	1.94	0.0333	AKT3,CAMK4,MAPK1,MAPK3,PRKAG2



Figure 3. Ingenuity Pathway Analysis (IPA). SNPs/gene outcomes from MR analysis were subjected to IPA. (A) Canonical signaling pathways in age at menarche and first birth. The adjusted P-values of the top 25 signaling pathways are listed. (B) Disease and functions in age at first birth and menarche. The adjusted Pvalue of the top 20 significantly involved diseases and functions are listed. (C) IPA network 1 and (D) IPA network 2. The genes from our post-MR analysis are in bold. Solid lines indicate direct connections, while dotted lines indicate indirect connections (circular arrows mean influence itself). Color coding: pink-receptors, green-enzymes, purple-channels, orange-other proteins.



Figure 4. The distributions of outcome age and risk according to age group of menarche and fist live 419 birth as well as number of births before and after correcting confounders. Condition Baseline, no 420 confounder was corrected. Conditions Highest education and Lowest education, confounders of education, 421 smoking, and drinking were corrected, and bars were painted based on most smoking and drinking situations 422 with the highest and lowest education levels. Conditions Median education with BMI 18.5-24.9, Median 423 education with BMI 25-29.9, and Median education with BMI 30-, confounders of education, smoking, 424 drinking, and BMI were corrected, and bars were painted based on median education and most smoking and 425 drinking situation with 3 BMI categories. BMI, body mass index; HBP, high blood pressure; COPD, chronic 426 obstructive pulmonary disease; AD, Alzheimer's disease. 427

- 428
- 429
- 430

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 431 **References**

- 432 1 Medawer, P. B. An Unsolved Problem of Biology. (1952).
  433 2 Byars, S. G. & Voskarides, K. Antagonistic Pleiotropy in Human Disease. *J Mol Evol* 88, 12-25 (2020). <u>https://doi.org:10.1007/s00239-</u>
- 434 019-09923-2
  435 3 Wang, Z. & Cong, H. Antagonistic pleiotropy can promote adaptation to patchy environments. *Evolution* **75**, 197-199 (2021).
  436 https://doi.org:10.1111/evo.14133
- 437 4 Kumar, J. *et al.* Zinc Levels Modulate Lifespan through Multiple Longevity Pathways in Caenorhabditis elegans. *PLoS One* **11**, 438 e0153513 (2016). <u>https://doi.org:10.1371/journal.pone.0153513</u>
- 4395Grundy, E. & Tomassini, C. Fertility history and health in later life: a record linkage study in England and Wales. Soc Sci Med 61, 217-440228 (2005). <a href="https://doi.org:10.1016/j.socscimed.2004.11.046">https://doi.org:10.1016/j.socscimed.2004.11.046</a>
- 441 6 Day, F. R. *et al.* Physical and neurobehavioral determinants of reproductive onset and success. *Nat Genet* 48, 617-623 (2016).
   442 https://doi.org:10.1038/ng.3551
- Loh, P. R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for biobank-scale datasets. *Nat Genet* 50, 906-908 (2018). https://doi.org:10.1038/s41588-018-0144-6
- Mills, M. C. *et al.* Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. *Nat Hum Behav*5, 1717-1730 (2021). <u>https://doi.org:10.1038/s41562-021-01135-3</u>
- 9 Ng, J. C. M. & Schooling, C. M. Effect of basal metabolic rate on lifespan: a sex-specific Mendelian randomization study. *Sci Rep* 13, 7761 (2023). <u>https://doi.org:10.1038/s41598-023-34410-6</u>
- Williams, D. M., Jylhava, J., Pedersen, N. L. & Hagg, S. A Frailty Index for UK Biobank Participants. *J Gerontol A Biol Sci Med Sci* 74, 582-587 (2019). <u>https://doi.org:10.1093/gerona/gly094</u>
- 45111Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).452<a href="https://doi.org:10.1038/nature14177">https://doi.org:10.1038/nature14177</a>
- 45312Silva-Garcia, C. G. *et al.* The CRTC-1 transcriptional domain is required for COMPASS complex-mediated longevity in C. elegans. *Nat*454Aging 3, 1358-1371 (2023). <a href="https://doi.org/10.1038/s43587-023-00517-8">https://doi.org/10.1038/s43587-023-00517-8</a>
- 455 13 Mendioroz, M. *et al.* CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer's disease. *Alzheimers Res Ther* 456 8, 15 (2016). <u>https://doi.org:10.1186/s13195-016-0183-0</u>
- Liu, Y. *et al.* CHAC1 as a Novel Contributor of Ferroptosis in Retinal Pigment Epithelial Cells with Oxidative Damage. *Int J Mol Sci* 24 (2023). <u>https://doi.org:10.3390/ijms24021582</u>
- 45915Li, J. et al. CHAC1 inactivation is effective to preserve muscle glutathione but is insufficient to protect against muscle wasting in<br/>cachexia. PLoS One 18, e0283806 (2023). <a href="https://doi.org:10.1371/journal.pone.0283806">https://doi.org:10.1371/journal.pone.0283806</a>
- 46116Cloos, P. A. & Christgau, S. Post-translational modifications of proteins: implications for aging, antigen recognition, and<br/>autoimmunity. *Biogerontology* 5, 139-158 (2004). <a href="https://doi.org/10.1023/B:BGEN.0000031152.31352.8b">https://doi.org/10.1023/B:BGEN.0000031152.31352.8b</a>
- 46317Udenwobele, D. I. *et al.* Myristoylation: An Important Protein Modification in the Immune Response. *Front Immunol* 8, 751 (2017).464https://doi.org:10.3389/fimmu.2017.00751
- 46518Hayashi, N. & Titani, K. N-myristoylated proteins, key components in intracellular signal transduction systems enabling rapid and466flexible cell responses. Proc Jpn Acad Ser B Phys Biol Sci 86, 494-508 (2010). <a href="https://doi.org:10.2183/pjab.86.494">https://doi.org:10.2183/pjab.86.494</a>
- 46719Wen, Z. et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat468Immunol 20, 313-325 (2019). <a href="https://doi.org:10.1038/s41590-018-0296-7">https://doi.org:10.1038/s41590-018-0296-7</a>
- Liang, J. *et al.* Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. *Nat Commun* 6, 7926 (2015). <u>https://doi.org:10.1038/ncomms8926</u>
- 471 21 McHugh, D. *et al.* COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells. *Nat Cell Biol* 25, 1804 472 1820 (2023). <u>https://doi.org:10.1038/s41556-023-01287-6</u>
- 47322Thinon, E., Morales-Sanfrutos, J., Mann, D. J. & Tate, E. W. N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and474Apoptosis in Cancer Cells. ACS Chem Biol 11, 2165-2176 (2016). <a href="https://doi.org/10.1021/acschembio.6b00371">https://doi.org/10.1021/acschembio.6b00371</a>
- 47523Zhu, G. *et al.* N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating476Ubiquitination of Targets. *Front Oncol* **11**, 681366 (2021). <a href="https://doi.org.10.3389/fonc.2021.681366">https://doi.org.10.3389/fonc.2021.681366</a>
- 477 24 Tomita, Y. *et al.* Targeting N-Myristoylation Through NMT2 Prevents Cardiac Hypertrophy and Heart Failure. *JACC Basic Transl Sci* 8, 1263-1282 (2023). <u>https://doi.org:10.1016/j.jacbts.2023.06.006</u>
- 479 25 Ashrafi, K., Lin, S. S., Manchester, J. K. & Gordon, J. I. Sip2p and its partner snf1p kinase affect aging in S. cerevisiae. *Genes Dev* 14, 1872-1885 (2000).
- 481 26 Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* 30, 523-530 (2014). <u>https://doi.org:10.1093/bioinformatics/btt703</u>
- 483 27 Gaulton, A. *et al.* ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res* 40, D1100-1107 (2012). 484 https://doi.org:10.1093/nar/gkr777
- Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* 46, D1074-D1082 (2018).
   <a href="https://doi.org:10.1093/nar/gkx1037">https://doi.org:10.1093/nar/gkx1037</a>
- 487 29 Guo, H. J., Ye, Y. L., Gao, Y. F. & Liu, Z. H. Age at first birth is associated with the likelihood of frailty in middle-aged and older women:
  488 A population-based analysis from NHANES 1999-2018. *Maturitas* 181, 107904 (2023).
  489 https://doi.org:10.1016/j.maturitas.2023.107904
- 490 30 Long, E. & Zhang, J. Evidence for the role of selection for reproductively advantageous alleles in human aging. *Sci Adv* **9**, eadh4990 (2023). <a href="https://doi.org:10.1126/sciadv.adh4990">https://doi.org:10.1126/sciadv.adh4990</a>
- 492 31 Liu, D. *et al.* Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational Studies, Randomized Controlled Trials, and Mendelian Randomization Studies. *Adv Nutr* 13, 1044-1062 (2022). <u>https://doi.org:10.1093/advances/nmab142</u>
- 49432Chen, X. *et al.* Kidney damage causally affects the brain cortical structure: A Mendelian randomization study. *EBioMedicine* 72,495103592 (2021). <a href="https://doi.org/10.1016/j.ebiom.2021.103592">https://doi.org/10.1016/j.ebiom.2021.103592</a>
- 49633Barth, C. & de Lange, A. G. Towards an understanding of women's brain aging: the immunology of pregnancy and menopause. Front497Neuroendocrinol 58, 100850 (2020). <a href="https://doi.org:10.1016/j.yfrne.2020.100850">https://doi.org:10.1016/j.yfrne.2020.100850</a>

100	24	Channin D. D. & Hannin L. C. During an advictor the mount and the formula of advice of advice on advice on advice of a series in
490	34	snerwin, B. B. & Henry, J. F. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in
499		women: a critical review. Front Neuroendocrinol 29, 88-113 (2008). https://doi.org:10.1016/j.yfrne.2007.08.002
500	35	Goldsmith T. C. Aging as an evolved characteristic - Weismann's theory reconsidered. Med Hynotheses 62 304-308 (2004)
500	55	Goldsmith, T. C. Aging as an evolved characteristic - weisinging theory reconsidered. <i>Neu Hypotheses</i> <b>62</b> , 304-308 (2004).
501		https://doi.org:10.1016/S0306-9877(03)00337-2
502	36	Jorge, S., Chang, S., Barzilai, J. J., Leppert, P. & Segars, J. H. Mechanical signaling in reproductive tissues; mechanisms and
503		importance Reprod Sci 21 1002 1107 (2014) https://doi.org/10.1177/1922710114542022
505		importance. hep/ou/size1, 1035-1107 (2014). https://doi.org.10.1177/1555715114542025
504	37	Baumgarten, S. C., Armouti, M., Ko, C. & Stocco, C. IGF1R Expression in Ovarian Granulosa Cells Is Essential for Steroidogenesis,
505		Follicle Survival, and Fertility in Female Mice, Endocrinology 158, 2309-2318 (2017), https://doi.org.10.1210/en.2017-00146
506	20	Potkiaor L. A. et al. Dynamics of IGE signalling during the avulatory pack in woman undergoing ovarian stimulation. <i>I Clin Endocrinol</i>
500	30	botkjær, J. A. et ul. Dynamics of Gr Signaming during the ovulatory peak in women undergoing ovarian stimulation. J Cim Endocrino
507		Metab (2024). https://doi.org:10.1210/clinem/dgae132
508	39	Stubbs, S. A. <i>et al.</i> Role of Insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries. <i>J Clin</i>
500		Endowing Match 09, 2209, 220F (2012) https://doi.org/10.1210/ic.2012.1279
509		Endocrinol Metab 98, 3298-3305 (2013). https://doi.org.10.1210/jc.2013-1378
510	40	Papaconstantinou, J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. Mol Cell Endocrinol
511		<b>299</b> , 89-100 (2009), https://doi.org:10.1016/i.mce.2008.11.025
512	/11	Kolman S. M. Efforts of oral contracontives. Annu Pay Pharmacol 9, 262, 278 (1960)
512	41	Rainfail, 3. M. Effects of oral contraceptives. Annu nev Phurmucol 9, 505-578 (1909).
513		https://doi.org:10.1146/annurev.pa.09.040169.002051
514	42	van Heemst, D. Insulin, IGF-1 and longevity. Aging Dis 1, 147-157 (2010).
515	13	Junnila R.K. List F.O. Berryman, D.F. Murrey, J.W.& Konchick, J.J. The GH/IGE-1 avis in againg and longevity. Nat Rev Endocrinol
515	45	Julinia, K. K., Elst, E. O., Berlyman, D. L., Mulley, J. W. & Ropenick, J. J. The Griffer-1 axis in ageing and longevity. Nat Nev Endocrino
516		9, 366-376 (2013). <u>https://doi.org:10.1038/nrendo.2013.67</u>
517	44	Aleandri, V., Spina, V. & Ciardo, A. [The role of the pineal body in the endocrine control of puberty], <i>Minerva Ginecol</i> 49, 43-48
518		(1007)
510		(1997).
519	45	Olcese, J. M. Melatonin and Female Reproduction: An Expanding Universe. Front Endocrinol (Lausanne) <b>11</b> , 85 (2020).
520		https://doi.org:10.3389/fendo.2020.00085
520 521	10	Chan D. Zhao M. & Mundu C. D. Dana manufagenetic proteins. Crowth Factors <b>22</b> , 222, 241 (2004)
521	40	chen, D., Zhao, M. & Munay, G. R. Bone morphogenetic proteins. Growth Factors 22, 233-241 (2004).
522		https://doi.org:10.1080/08977190412331279890
523	47	Magro-Lopez, F. & Munoz-Fernandez, M. A. The Role of BMP Signaling in Female Reproductive System Development and Function.
E 2 4	.,	
524		Int J Mol Sci <b>22</b> (2021). <u>https://doi.org:10.3390/IJmS22211192/</u>
525	48	Childs, A. J. <i>et al</i> . BMP signaling in the human fetal ovary is developmentally regulated and promotes primordial germ cell apoptosis.
526		Stem Cells 28 1368-1378 (2010) https://doi.org.10.1002/stem 440
520	40	de Contra E V (2007) and a state of the sector of the sect
527	49	da cunna, E. V. et al. Effects of bone morphogenetic protein 4 (BNP4) on in vitro development and survival of bovine preantrai
528		follicles enclosed in fragments ovarian tissue. Zygote 25, 256-264 (2017). <u>https://doi.org:10.1017/S0967199417000089</u>
529	50	7hang X et al. BMP4 overexpression induces the unregulation of APP/Tau and memory deficits in Alzheimer's disease. Cell Death
E20	50	
550		$D(scov 7, 51 (2021). \frac{nttps://doi.org:10.1038/s41420-021-00435-x}{100435-x})$
531	51	Meyers, E. A. <i>et al.</i> Increased bone morphogenetic protein signaling contributes to age-related declines in neurogenesis and
532		cognition. Neuropial Aging 38, 164-175 (2016), https://doi.org:10.1016/i.neuropialaging.2015.10.035
E 2 2	52	
222	52	Ye, D. et al. insights into bone morphogenetic proteins in cardiovascular diseases. Front Pharmacol <b>14</b> , 1125642 (2023).
534		https://doi.org:10.3389/fphar.2023.1125642
535	53	Baboota, R. K., Bluher, M. & Smith, U. Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders, Diabetes 70, 303-312
E 2 6		
530		(2021). <u>https://doi.org:10.2337/db20-0884</u>
537	54	Saenger, P. Dose effects of growth hormone during puberty. Horm Res 60, 52-57 (2003). https://doi.org:10.1159/000071226
538	55	Bartke, A. Growth hormone and aging. Rev Endocr Metab Disord 22, 71-80 (2021), https://doi.org.10.1007/s11154-020-09593-2
520	55	Kaleys L. Alesking D. S. Anger M. A Bala of DI2K (Alt Signaling in Constant Mutricing and East) From Disking D. S. Anger M. A Bala of DI2K (Alt Signaling in Constant Mutricing and East) From Disking Disking and Constant College (1)
223	50	Raious, J., Alesnkina, D. & Anger, M. A Role of PI3K/Akt Signaling in Oocyte Maturation and Early Embryo Development. Cells 12
540		(2023). https://doi.org:10.3390/cells12141830
541	57	Chung, E., Yeung, F. & Leinwand, L. A. Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation, J Appl Physiol (1985)
542		412 1564 1575 (2012) https://doi.org/10.1152/journehusiol.00027.2012
542		<b>112</b> , 1504-1575 (2012). <u>https://doi.org.10.1152/jappipinysioi.00027.2012</u>
543	58	Chen, Y. R. et al. Aging-induced Akt activation involves in aging-related pathologies and Abeta-induced toxicity. Aging Cell 18, e12989
544		(2019), https://doi.org:10.1111/acel.12989
	50	Lever ( C. D. Interpretation of concoductive between a before, during and ofter the subortal transition Identifying health and
545	59	Howard, S. R. Interpretation of reproductive normones before, during and after the publicial transition-identifying health and
546		disordered puberty. Clin Endocrinol (Oxf) 95, 702-715 (2021). https://doi.org:10.1111/cen.14578
547	60	Bhartiya, D., Sriraman, K., Gunial, P. & Modak, H. Gonadotropin treatment augments postnatal oogenesis and primordial follicle
510		accomble in adult marks outparts 1 August and Base 22 (2012) https://doi.org/10.1106/0757.2016.5.20
540		assembly in adult mouse ovaries? J Ovarian Res 5, 32 (2012). https://doi.org/10.1186/1757-2215-5-32
549	61	Danilovich, N., Javeshghani, D., Xing, W. & Sairam, M. R. Endocrine alterations and signaling changes associated with declining
550		ovarian function and advanced biological aging in follicle-stimulating hormone recentor handoinsufficient mice. Biol Benrod 67, 370-
221		378 (2002). <u>https://doi.org:tu.tu95/bioireproab7.2.370</u>
552	62	Hale, G. E. et al. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified
553		according to the Staging of Reproductive Aging Workshon (STRAW) staging system / Clin Endocrinol Metah 92, 3060-3067 (2007)
JJ4		<u>nttps://doi.org.t0.1210/jC.2007-0066</u>
555	63	Santoro, N. & Randolph, J. F., Jr. Reproductive hormones and the menopause transition. <i>Obstet Gynecol Clin North Am</i> <b>38</b> , 455-466
556		(2011), https://doi.org:10.1016/i.ogc.2011.05.004
557	61	Vanden Brink Later Associations Potware Astronomics Folliele Dunamics and Harmana Braductics Throughout the Marstraud
JJ/	04	vanuen brink, n. et ul. Associations between Antrai Ovarian Follicle Dynamics and Hormone Production Infougnout the Menstrual
558		Cycle as Women Age. J Clin Endocrinol Metab 100, 4553-4562 (2015). https://doi.org:10.1210/jc.2015-2643
559	65	Plotnikov, A., Zehorai, F., Procaccia, S. & Seger, R. The MAPK cascades: signaling components, nuclear roles and mechanisms of
560		nucleon transformed and the second state 1913 and the second states of the second states and t
200		nuclear translocation. <i>Biochim Biophys Acta</i> 1615, 1619-1633 (2011). <u>https://doi.org/10.1016/j.bbamcr.2010.12.012</u>
561	66	Zhang, W. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. <i>Cell Res</i> <b>12</b> , 9-18 (2002).
562		https://doi.org/10.1038/si.cr.7290105
562	67	
203	ט/	ruan, w. et al. Modulating p38 MAPK signaling by proteostasis mechanisms supports tissue integrity during growth and aging. Nat
564		Commun 14, 4543 (2023). https://doi.org:10.1038/s41467-023-40317-7
565	68	An. Y. et al. Oridonin Delays Aging Through the AKT Signaling Pathway, Front Pharmacol 13, 888247 (2022)
566		https://doi.org/10.2200/fabr/2022.99977
JUU		11(10).//001.018.10.0007/10101.2022.00024/

- medRxiv preprint doi: https://doi.org/10.1101/2024.09.23.24314197; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 567 69 Abdellatif, M. et al. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity. Circulation 568 145, 1853-1866 (2022). https://doi.org:10.1161/CIRCULATIONAHA.122.059863 569 70 Lundgren, S. et al. BMI is positively associated with accelerated epigenetic aging in twin pairs discordant for body mass index. J Intern 570 Med 292, 627-640 (2022). https://doi.org:10.1111/joim.13528 571 71 Quach, A. et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. Aging (Albany NY) 9, 419-446 (2017). 572 https://doi.org:10.18632/aging.101168 573 Wilson, K. A. et al. Evaluating the beneficial effects of dietary restrictions: A framework for precision nutrigeroscience. Cell Metab 33, 72 574 2142-2173 (2021). https://doi.org:10.1016/j.cmet.2021.08.018 575 Balasch, J. Ageing and infertility: an overview. Gynecol Endocrinol 26, 855-860 (2010). 73 576 https://doi.org:10.3109/09513590.2010.501889 577 74 Atkins, J. L. et al. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging Cell 20, e13459 578 (2021). https://doi.org:10.1111/acel.13459 579 75 Pilling, L. C. et al. Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. Aging (Albany NY) 9, 2504-2520 580 (2017). https://doi.org:10.18632/aging.101334 581 76 McCartney, D. L. et al. Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome 582 Biol 22, 194 (2021). https://doi.org:10.1186/s13059-021-02398-9 583 77 Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, 584 immunity and lipid processing. Nat Genet 51, 414-430 (2019). https://doi.org:10.1038/s41588-019-0358-2 Donertas, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M. Common genetic associations between age-related 585 78 586 diseases. Nat Aging 1, 400-412 (2021). https://doi.org:10.1038/s43587-021-00051-5 587 Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 53, 1415-1424 (2021). 79 588 https://doi.org:10.1038/s41588-021-00931-x 589 80 Ahadi, S. et al. Longitudinal fundus imaging and its genome-wide association analysis provide evidence for a human retinal aging 590 clock. Elife 12 (2023). https://doi.org:10.7554/eLife.82364 591 Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 570, 514-518 (2019). 81 592 https://doi.org:10.1038/s41586-019-1310-4 593 O'Mara, T. A. et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9, 3166 (2018). 82 594 https://doi.org:10.1038/s41467-018-05427-7 595 Savage, J. E. et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to 83 596 intelligence. Nat Genet 50, 912-919 (2018). https://doi.org:10.1038/s41588-018-0152-6 597 84 Gao, X. et al. The bidirectional causal relationships of insomnia with five major psychiatric disorders: A Mendelian randomization 598 study. Eur Psychiatry 60, 79-85 (2019). https://doi.org:10.1016/j.eurpsy.2019.05.004 599 85 Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 32, 3207-3209 (2016). 600 https://doi.org:10.1093/bioinformatics/btw373 601 86 Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 602 4851-4853 (2019). https://doi.org:10.1093/bioinformatics/btz469 603 Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for Mendelian randomization. Stat Methods 87 604 Med Res 26, 2333-2355 (2017). https://doi.org:10.1177/0962280215597579 605 Venkateswaran, S. et al. Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflamm Bowel Dis 24, 829-838 (2018). 88 606 https://doi.org:10.1093/ibd/izx084 607 Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet 17, e1009440 89 608 (2021). https://doi.org:10.1371/journal.pgen.1009440 609 Ghosh, S. et al. Core Canonical Pathways Involved in Developing Human Glioblastoma Multiforme (GBM). Int J Sci Res Sci Eng Technol 90 610 3, 458-465 (2017).
- 611